Preliminary data shows that BNT 162b1 is safe and immunologically active in COVID-19.- Pfizer and BioNTech
Pfizer and BioNTech announced preliminary data from the most advanced of four investigational vaccine candidates from their BNT 162 mRNA-based vaccine program, Project Lightspeed, against SARS-CoV-2. The BNT… read more.